Navigation Links
Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive

MONMOUTH JUNCTION, N.J., Jan. 25, 2012 /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company announced joining of a highly regarded Big Pharma executive Dr. Mahdi Fawzi to its leadership position as the Chief Scientific Officer and Executive Vice President of R&D including Regulatory Affairs.  

Throughout his career Dr. Fawzi has helped create a huge value as exemplified having many blockbuster drugs developed under his leadership such as Lipitor®, Enbrel®, Protonix®, Effexor XR®, Rapamune®, and Pristiq® among other.  Most recently Dr. Fawzi was President, Global Research & Development at Warner Chilcott where he led approval of Atelvia™ and Loestrin 24Fe, and managed integration of P&G's Pharmaceutical R&D operation. From 1995 to 2009, Dr. Fawzi was part of senior leadership team at Wyeth including last five years as Executive Vice President of Preclinical Development. Under his leadership Wyeth advanced 91 new molecules, filed 70 INDs, and 10 NDAs over last seven years prior to Pfizer merger. He oversaw 1300 scientists worldwide and managed a budget of over a quarter billion dollars. While at Wyeth, he won several prestigious industry awards and was one of the four finalists in 2004 for the Pharmaceutical Executive of the Year Award. He also held senior management positions at Warner Lambert and P&G. He is an author or co-author of over 50 publications and awarded more than 80 patents. He is a pharmacist by education and earned his M.S. and Ph.D. in Pharmaceutical Chemistry at University of Michigan.

"We are fortunate to have someone of Dr. Fawzi's caliber lead Tris R&D. Mahdi will lead our development, strengthen research base of various technology initiatives that are underway, direct clinical and regulatory disciplines," said Ketan Mehta, Tris' President and CEO. "Dr. Yu-Hsing Tu, who has led R&D for last ten years will focus on product development and report to Mahdi." 

"I am truly excited to be part of Tris' pioneering work involving new technologies, especially OralXR+ platform and its application in liquid and other unique dosage forms," stated Dr. Mahdi Fawzi. "Tris has accomplished a great deal in its relatively short history and I look forward to building upon the successes Dr. Tu and the R&D team has had to date."

About Tris Pharma

Tris Pharma is an emerging specialty pharmaceutical company focused on the research and development of drug delivery technologies based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit

SOURCE Tris Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:11/24/2015)... and BERN, Switzerland , November ... ARTORG Center for Biomedical Engineering Research of the University ... Division of Endocrinology, Diabetes and Clinical Nutrition of the ... start of an exclusive collaboration to develop a novel ... for the personalised delivery of insulin for diabetic patients ...
(Date:11/24/2015)... FLINT, Mich. , Nov. 24, 2015 Diplomat ... , Senior Vice President of Clinical Services, Education and Human ... (AIS) online webinar, "Oral Oncology Drugs: Health Plan Strategies for ... co-presenting with Beckie Fenrick , a consultant with the ... The webinar will ...
(Date:11/24/2015)... , Nov. 24, 2015 iRhythm Technologies, Inc. , ... care, today announced that it will participate in the 27th Annual ... New York, NY . Kevin King ... Tuesday December 1, 2015 at 8:50am ET. ... . --> . --> ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 2015 , ... Young patients with a wide variety of dental needs can ... S. Lele, who are pediatric dentists in Tucson, AZ . Unlike traditional treatment ... system causes minimal discomfort and bleeding to the patient during treatment and the following ...
(Date:11/24/2015)... ... November 25, 2015 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... upcoming Clinical Trial Supply East Asia Conference, to be held at the InterContinental ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... advisory organization, is pleased to welcome Winter-Dent & Company as its newest Partner ... day one to become a client's most trusted advisor regardless of whether that ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Serenity Point Rehabilitation, ... series of recent video interviews with some of the staff members at their recovery ... residential treatment facility, as well as some of the things that make their recovery ...
Breaking Medicine News(10 mins):